Recently, we developed a technique that allows the in uiuo visualization
Radiotherapy of such tumors using somatostatin analogs coupled to OL-or P-emitting radionuclides has been proposed as an application for radiolabeled somatostatin analogs. To develop this concept further, it is of importance to know whether the above-mentioned radiolabeled somatostatin analogs are internalized by the tumor cells, and whether it might be possible to manipulate the degree of internalization.
In the present study we investigated the internalization of a stable somatostatin analog, (SS-R) are present in all normal target tissues of the peptide, such as brain, anterior pituitary gland, and pancreas. In a variety of human tumors, frequently originating from normal somatostatin (SS) target tissues, high numbers of SS-R can be detected by classical biochemical binding techniques as well as by in vitro autoradiography. These tumors include those with amine precursor uptake and decarboxylation characteristics (pituitary tumors, endocrine pancreatic tumors, carcinoids, paragangliomas, small cell lung cancers, medullary thyroid carcinomas, and pheochromocytomas) as well as meningiomas, well differentiated brain tumors (astrocytomas), neuroblastomas, lymphomas, and some human breast cancers (1). Recently, we developed a technique that allows the in viva visualiza-tion in man of the above-mentioned SS-R-positive tumors after iv injection of [iz31-Tyr3]octreotide (2,3) or . Using this technique, we showed that certain tumors, especially those with a high number of SS-R, could be visualized 48 h after injection (l-4). This rather long residence time of radioactivity on human tumors in viuo suggests that the radioligand is internalized by the tumor cells. Internalization of radioligand is of special importance when radiotherapy of certain SS-R-positive human cancers with CX-or p-emitting isotopes coupled to SS analogs is considered (5, 6).
At present, equivocal data have been reported with respect to internalization of SS. Receptor-mediated endocytosis of SS has been demonstrated in rat anterior pituitary cells and rat islet cells (7) (8) (9) (10) (11) (12) (13) (14) , whereas other investigators found that [lz51-Tyr']SS-14 and ['251-Tyr"]SS-14 are not rapidly internalized by GH,C, rat pituitary cells and RINm5F insulinoma cells, respectively, probably due to degradation of these radioligands at the cell surface (15, 16) . As data with respect to internalization of SS may have been influenced by the susceptibility to degradation of the SS ligands used in the above- broken cell preparation of AtT20 cells in a dose-dependent fashion, with an IC,, of 0.1 nM (Fig. 3C) .
The increased internalization of [1251-Tyr"]octreotide induced by this low amount (1 nM) of unlabeled octreotide occurred very rapidly (Fig. 4) . Unlabeled octreotide (1 PM) completely blocked internalization of the radioligand by 15 min of incubation (P < 0.01 us. control cells), whereas 1 nM octreotide nearly doubled internalization at this time point (P < 0.01 'us. control cells). Because the increased internalization seems to occur very rapidly, we also studied the effect of 1 nM unlabeled octreotide at several time points between O-2.5 min of incubation.
The results of these experiments are shown in Fig. 5 Similar to the observations in AtT20 cells, human GHsecreting pituitary adenoma cells from patient 1 showed a time-dependent specific membrane binding (Fig. 6 , upper panel) and internalization of 1'251-Tyr310ctreotide (Fig. 6,  lower panel) . In the presence of 1 nM unlabeled octreotide, a rapid increase in both membrane-bound and internalized radioligand was observed. A statistically significant higher amount of radioligand was bound and internalized at all time points studied. After 60 min of incubation, an approximately 6-fold higher amount of radioligand was bound and internalized in the presence of 1 nM unlabeled octreotide compared to that in control cells (specific binding of control cells, 0.2% VS. 1.3% at 1 nM octreotide; specific internalization by control cells, 0.4% us. 2.5% at 1 nM octreotide). The total amounts of radioligand bound and V."" -0.00 0.50 n P < 0.01 US. control.
internalized by these GH-secreting pituitary adenoma cells after 4-h incubation were also high (1.28% and 4.98% of the dose of radioligand added, respectively).
The effect of 1 nM unlabeled octreotide was further investigated in six other GH-secreting adenoma cell cultures. Table 2 shows that the amount of internalized radioligand was significantly increased (32-122% increase) by 1 nM octreotide in five of six cultures (no. 1, 4, 5, 6, and 7), which showed internalization of the radioligand, whereas the amount of membrane-bound radioligand was simultaneously increased in three of six cultures (no. 1, 6, and 7; 30-113% increase). Cultured cells from patient 3 showed no binding and internalization, whereas 1 nM octreotide significantly lowered internalization by the cultured cells of patient 2. Comparable to the findings in AtT20 cells, displacement of internalization of octreotide by cells of patient 4 showed a bell-shaped curve, with a maximal increase by 1 nM unlabeled octreotide and saturation at higher octreotide concentrations (not shown).
Interestingly, we found that the preoperative SC administration of 50 pg octreotide induced a significant lowering of serum GH levels in patients 1 and 2, whereas patients 3 and 4 showed no response of GH levels to octreotide in viva (Fig.  7) . In support of this sensitivity to octreotide in vim, we observed that GH release by cultured cells from patients 1 and 2 was significantly more sensitive to octreotide in vitro than that by cultured tumor cells from patients 3 and 4. GH release by cultured tumor cells from patients 1,2,3, and 4 was inhibited by octreotide (10 nM) by 83 + 9%, 43 + 2%, 27 t l%, and 16 + 0%, respectively.
GH release by cells of patients 5,6, and 7 was inhibited by 43 k l%, 25 k l%, and 27 + l%, respectively. Thus, the cells of patients 1 and 5, which showed a high amount of internalization of [1251-Tyr3] study showed that pertussis toxin reduced the affinity of SS-R for SS (and its structural analogs) in AtT20 cells (27) . In addition, internalization of octreotide by human GH-secreting pituitary tumor cells was found. Several studies have demonstrated receptor-mediated endocytosis of SS in rat anterior pituitary cells (7, 9, 11, 12) , rat islet cells (10, 14) , and AtT20 cells (8). Other investigators, however, showed that [iz51-Tyr']SS-14 and ['251-Tyr"]SS-14, unlike ['251 ]epidermal growth factor, are not rapidly internalized by GH,C, rat pituitary cells and RINm5F insulinoma cells, respectively (15, 16). These investigators suggested that the radioligands they used were rapidly degraded by membrane proteases. From our present study, it is clear that a high amount of the radioiodinated SS analog Tyr"-octreotide is internalized by AtT20 mouse and human GH-secreting pituitary tumor cells. This is probably related to the high stability of octreotide (17). The parental cyclic octapeptide analog octreotide (SMS 201-995) was shown to be highly resistant to degradation by pure enzymes and tissue homogenates (28). In agreement with this, we found that most of the radioactivity present in the cells after 4 h of incubation was still peptide bound, although we did not perform HPLC analysis to demonstrate that the peptidebound radioactivity represented intact radioligand. In addition, inhibitors of lysosomal degradation (chloroquine and NH&l) did not increase the amount of acid-resistant (internalized) radioactivity. In fact, in agreement with a previous study by Presky and Schonbrunn (15) significantly inhibited the amount of internalized radioligand. It appears, therefore, that the inhibitory effect of chloroquine is due to direct interference with the process of receptor-mediated endocytosis, and that this latter effect prevails over its inhibitory effect on lysosomal function under the conditions of our study. Our data favor further development of the concept of radiotherapy using radiolabeled SS analogs.
Another finding of our present study is the rapidly increasing binding and internalization of ['251-Tyr310ctreotide when AtT20 cells and human GH-secreting adenoma cells are simultaneously incubated with a low concentration of unlabeled octreotide. Displacement of binding and internalization of radioligand by AtT20 cells by unlabeled octreotide showed a bell-shaped curve at 37 C. An increase was found at low unlabeled octreotide concentrations (0.1 and 1 nM), whereas at higher concentrations, saturation was observed. In contrast to this, displacement of binding by unlabeled octreotide to a broken cell preparation of AtT20 cells showed, under the same incubation conditions, a dose-dependent inhibition curve with an IQ,, of 0.1 nM, in agreement with the estimated K, of the SS-R on these cells. This suggests that binding of In our study we also found that unlabeled SS-14 and SS-28 induced this increase in AtT20 cells (data not shown).
At present, we have no explanation for the mechanism of the increased binding and subsequent internalization of [12'1-Tyr"]octreotide by AtT20 tumor cells and human GH-secreting adenoma cells induced by simultaneous incubation with a low concentration of unlabeled octreotide.
The rapid increase in ['2"I-Tyr"]octreotide binding and internalization seems unlikely to be caused by de ~zuuo synthesis of SS-R, because this increase occurred within several minutes of incubation with 1 nM unlabeled octreotide. Therefore, the most likely explanation for this phenomenon is a rapid recruitment of cellular SS-R to the outside of the cell membrane, although an increased internalization rate or an effect of octreotide on SS-R synthesis cannot be fully excluded. In this respect, it should be mentioned that glucose has been shown to increase the amount of internalized SS in pancreatic islets, probably due in part to the increase in the cell surface SS-R concentration by migration of the secretion vesicles during emiocytosis, promoting increased transport of SS-R (33). Short term pretreatment of AtT20 cells with 1 nM octreotide did not result in a significant change in the estimated K, of ['2"I-Tyr"]octreotide binding (our unpublished observation), indicating that the increased internalization is not caused by an augmented affinity of the receptor. Recently, at least five different SS-R subtypes have been cloned. All subtypes bind SS-14 and SS-28 with high affinity, whereas their affinities for numerous SS analogs differ considerably (34-39). Octreotide binds with high affinity to the human SSTR2 (hSSTR2) subtype, whereas this analog has a moderate affinity to hSSTR3 and hSSTR5 subtypes and shows no binding to the hSSTR subtypes 1 and 4 (34-39). More than one hSSTR subtype is expressed in human GHsecreting adenomas. Greenman and Melmed (40, 41) showed in 3 of 7, 9 of 10, 6 of 7, 0 of 11, and 10 of 11 human GH-secreting adenomas, expression of hSSTR1, hSSTR2, hSSTR3, hSSTR4, and hSSTR5, respectively.
In addition, Reubi et al. (42) (pituitary, pancreas, and adrenals) in rats showed a bell-shaped function of the injected mass (18). Therefore, the highest specific radioactivity may not automatically result in the highest binding and subsequent internalization of the radioligand by the tumor in in viva SS-R imaging using radiolabeled SS analogs in patients with SS-R-positive tumors. Indeed, preliminary findings in patients indicate that scintigra'phy with a specific activity higher than 220 megabecquerels ' 'In/5 PLg [DTPA-o-Phe'loctreotide will lead to decreased quality, and uptake in tumors will be significantly reduced (45). Moreover, Dorr et nl. (46) 
